<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02729116</url>
  </required_header>
  <id_info>
    <org_study_id>HE581520</org_study_id>
    <nct_id>NCT02729116</nct_id>
  </id_info>
  <brief_title>Sitafloxacin and Ertapenem Treatment for Acute Urinary Tract Infection Caused by E. Coli or K. Pneumoniae in Post-kidney Transplantation Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates oral antimicrobial agents for the treatment of non-bacteremic acute
      urinary tract infection caused by Extended Spectrum Beta Lactamase producing Escherichia coli
      or Klebsiella pneumoniae in Post-kidney transplantation. Patients are treated with
      intravenous (IV) antibiotics follow by oral sitafloxacin or IV ertapenem.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A prospective randomized controlled trial of patients with a presumptive diagnosis of acute
      urinary tract infection caused by Extended Spectrum Beta Lactamase-producing Escherichia coli
      or Klebsiella pneumoniae in Post-kidney transplantation. Intravenous (IV) antibiotic is
      initially given to all patients. After day 3, patients were randomized to receive either oral
      sitafloxacin (100 mg twice daily) or intravenous ertapenem. The course of treatment will
      complete within 14 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with clinical cure of acute urinary tract infection</measure>
    <time_frame>14 days</time_frame>
    <description>No symptoms of acute urinary tract infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with micrological cure of acute urinary tract infection</measure>
    <time_frame>14 days</time_frame>
    <description>No evidence of Extended Spectrum Beta Lactamase Escherichia coli or Klebsiella pneumoniae in urine culture</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Anti-Infective Agents, Urinary</condition>
  <condition>Escherichia Coli Infections</condition>
  <condition>Klebsiella Infections</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Sitafloxacin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sitafloxacin 100 mg oral twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ertapenem group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ertapenem 1 gm IV every 24 h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitafloxacin</intervention_name>
    <description>Patients are given intravenous empirical antibiotics for 3 days. The patients are allocated to the sitafloxacin group or ertapenem group using of a computer-generated random number allocation schedule and block size of four.</description>
    <arm_group_label>Sitafloxacin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ertapenem</intervention_name>
    <description>Patients are given IV ertapenem for 14 days</description>
    <arm_group_label>Ertapenem group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Acute urinary infection by definitions

          -  Positive urine culture for Extended Spectrum Beta Lactamase E. coli or K. pneumoniae
             ≥105 colony forming unit/mL

          -  Post-kidney transplantation

          -  Voluntarily consented to be enrolled in the study

        Exclusion Criteria:

          -  Sepsis

          -  Positive blood culture

          -  Mixed organism of urine culture

          -  Immunocompromised conditions other than post-kidney transplantation

          -  Pregnancy or lactation

          -  Previous urinary tract infections within 4 weeks

          -  Contraindicated for fluoroquinolones and carbapenems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Khon Kaen University</name>
      <address>
        <city>Khonkaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Thamlikitkul V, Tiengrim S. In vitro susceptibility test of sitafloxacin against resistant gram-negative bacilli isolated from Thai patients by disk diffusion method. J Med Assoc Thai. 2014 Mar;97 Suppl 3:S7-12.</citation>
    <PMID>24772575</PMID>
  </reference>
  <reference>
    <citation>Nakamura T, Komatsu M, Yamasaki K, Fukuda S, Higuchi T, Ono T, Nishio H, Sueyoshi N, Kida K, Satoh K, Toda H, Toyokawa M, Nishi I, Sakamoto M, Akagi M, Mizutani T, Nakai I, Kofuku T, Orita T, Zikimoto T, Natsume S, Wada Y. Susceptibility of various oral antibacterial agents against extended spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae. J Infect Chemother. 2014 Jan;20(1):48-51. doi: 10.1016/j.jiac.2013.08.004. Epub 2013 Dec 11.</citation>
    <PMID>24462425</PMID>
  </reference>
  <reference>
    <citation>Tiengrim S, Phiboonbanakit D, Thunyaharn S, Tantisiriwat W, Santiwatanakul S, Susaengrat W, Srisurat N, Malithong A, Srisangchan P, Thamlikitkul V. Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections. J Med Assoc Thai. 2012 Feb;95 Suppl 2:S6-17.</citation>
    <PMID>22574524</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2016</study_first_submitted>
  <study_first_submitted_qc>March 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2016</study_first_posted>
  <last_update_submitted>August 15, 2017</last_update_submitted>
  <last_update_submitted_qc>August 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Atibordee Meesing, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Extended-Spectrum ß-lactamase-producing Escherichia coli</keyword>
  <keyword>Extended-Spectrum ß-lactamase-producing Klebsiella pneumoniae</keyword>
  <keyword>Kidney Transplantation</keyword>
  <keyword>Urinary Tract Infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Klebsiella Infections</mesh_term>
    <mesh_term>Escherichia coli Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ertapenem</mesh_term>
    <mesh_term>Sitafloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

